Introduction
The ALK gene (OMIM: 105590) was initially characterized as a fusion partner of the NPM-ALK oncogene and is now recognized as the active component in multiple fusion proteins in a variety of cancers (1) . Recent studies have reported putative activating ALK point mutations in both familial and sporadic cases of neuroblastoma, and in a number of neuroblastoma cell lines (2) (3) (4) (5) (6) . Neuroblastoma, which is derived from neural crest cells and can occur in the entire peripheral sympathetic nervous system, accounts for approximately 15% of all deaths in pediatric cancer (7) .
In this study we have identified a novel activating mutation in ALK in a neuroblastoma patient in the course of analysis of genomic DNA from patient biopsy samples. Initial analysis indicated a wild type ALK locus, which during disease progression, became mutated leading to the production of a F1174 ALK kinase domain mutation. In inducible cell lines expressing the F1174 ALK mutant as well as in the Drosophila model system we are able to (Fig. 1B) . Due to the extremely rapid growth a new biopsy including tumor genetic investigations was performed. A further course of TVD (topotecan, vincristine, doxorubicin) was given but the tumors progressed and he developed lung metastases and died six weeks after the last course, ten months after initial diagnosis.
Immunohistochemistry
Staining for Ki-67 (DAKO), NB84 (Novocastra), ALK-P (Abcam) and ALK (Abcam) was made using the DAKO Autostainer. The slides were rehydrated with Xylene followed by a series of alcohol dilutions and a rinse in buffer (DAKO 8007). PTLINK (DAKO) was used as 5 enzyme antigen retrieval method. Endogenous enzyme block was made during 5 minutes with EnVision FLEX Peroxidase-Blocking Reagent (DAKO). The antibodies (diluted at DAKO Company) were incubated at room temperature for 20 minutes. After a 5 minutes rinse in buffer the labelled polymer, EnVision FLEX/HRP (DAKO), was applied and incubated for 20 minutes with two additional rinses before the slides were incubated with substratechromogen, Substrate Working Solution (DAKO) for 10 minutes. The slides were ultimately rinsed and counterstained in EnVision FLEX Hematoxylin and mounted.
Genomics profile with SNP array
Microarray analyses of DNA from the tumor samples were performed using Affymetrix human 250K gene mapping arrays as described earlier (9, 10) . For primary data analysis the GDAS software (Affymetrix) was used, while genomic profiles were generated using CNAG (Copy Number Analyzer for Affymetrix GeneChip Mapping arrays) version 3.0 (Genome Laboratory, Tokyo University; http://www.genome.umin.jp; 11).
Detection of ALK mutation with DNA sequencing
The procedure for DNA sequencing and analysis of the ALK exons has been described earlier (2) .
Generation of human ALK mutant constructs in PC12 cells.
Human ALK full length cDNA in the pcDNA3 vector was a kind gift from Marc Vigny. A 1298 bp fragment corresponding to nucleotides 4061 to 5358 of wild type human ALK sequence (NCBI Reference Sequence: NM_004304.3) was PCR amplified using the following primers: 5'-TTCTCCGGCATCATGATTGTGTA -3' and 5'-TTGGACTGAGAGAATGCCATATT-3'. This PCR product was subcloned into pCRII-TOPO (Invitrogen, following manufacturer's instructions), and the resulting plasmid was used as template for generation of the 3521T→C point mutation, corresponding to the F1174S streptomycin, L-glutamine, 100 µg/ml G418 and 2 µg/ml puromycin at 37 °C and 5% CO 2 .
Cell culture
Cell clones were screened for ALK expression by induction with 1 µg/ml doxycycline for 24 hours prior to analysis by immunoblotting.
Neurite formation assay
PC12-cells 2x10 6 were transfected by electroporation, in a Amaxa electroporator, using 1. heat inactivated FBS and 0.5 mg/ml G418 (Invivogen, San Diego, CA, USA) until they reached confluence after 12 days, with replacement of medium each third day. Thereafter the cells were kept in DMEM with 5% heat inactivated FBS and 0,25mg/ml G418 for another 10 days, with replacement of medium each second day. Plates were washed with PBS and air dried, fixed with methanol for 20 min and stained with 0.2% crystal violet in 20% ethanol for 20 min followed by a short rinse in water.
The number of foci was determined by inspection under the naked eye.
Cell lysis, immunoprecipitation and immunoblotting
Cells were washed twice with ice cold PBS prior to harvest in lysis buffer (25mM Tris pH 8
Generation of human ALK mutant constructs in Drosophila melanogaster.
Prior to ligation of ALK F1174L and ALK F1174S from pcDNA3 into the Drosophila pUAST expression vector, a 898 bp fragment preceeding the translation start was removed to increase expression efficiency in Drosophila(details available upon request). All three constructs were subsequently subcloned into the EcoRI-NotI site of the pUAST Drosophila vector and the resulting constructs were verified by DNA sequencing analysis. Transgenic constructs were employed for the generation of transgenic fly strains (BestGene Inc, CA).
Fly strains and expression experiments.
Standard Drosophila husbandry procedures were followed. The following stocks were used: Drosophila by crossing the UAS-ALK transgenic flies to the pGMR-GAL4 driver. Fly crosses were kept at 25 °C. Eye discs from 3rd instar larvae were fixed in 4% formaldehyde, blocked in 5% NGS overnight at 4
• C, and stained with primary antibody anti-ALK mAb46 (13) and secondary antibody anti-mouse Cy3 (The Jackson Laboratory, Bar Harbor, ME). Fluorescent microscopy pictures of eye discs were taken on a Leica TCS SPE confocal microscope.
Electron microscopy pictures of adult fly eyes were taken on a Cambridge Stereoscan 360 iXP scanning electron microscope at the Electron Microscopy Platform at Umeå University.
Results and Discussion
The patient presented with an abdominal tumor mass and skeletal involvement without bone marrow involvement, at 11 months of age. Biopsy of the primary tumor at diagnosis showed undifferentiated neuroblastoma without amplification of MYCN. The SNP array genomic profiling performed at diagnosis (Fig 1A) did 
mutation not present in the germline DNA of the patient. It is tempting to speculate on a twostep genetic process in which (i) the ALK F1174S mutation arises on one of the two chromosome 2 copies in the tumor and that (ii) this copy is duplicated through a homologous recombination event with full retained heterozygosity for the proximal 2p and the whole 2q
arm. Thus, the primary tumor biopsy and the sample from the last biopsy were similar in that the two aberrations found at diagnosis (10q loss and 17q gain) were found also in the latter sample, but strikingly the latter sample differed in that it had gained an additional abberaration, a homozygotization of a large portion of chromosome region 2p including a novel homozygous F1174S mutation in ALK. This is the first described case of an ALK mutation shown to be acquired during the disease course, concomitant with a tumor progression "from bad to worse".
To investigate whether the ALK F1174S mutation was a major cause for the dramatic tumor progression we employed both Drosophila melanogaster and cell culture based systems to examine the nature of ALK
F1174S
. Drosophila melanogaster offers a number of advantages including the conservation of many molecular pathways with vertebrates. The Drosophila ALK receptor tyrosine kinase (RTK) mediates activation of the ERK pathway in the developing visceral mesoderm (14-17), a signaling pathway which is crucial for the formation of the fly gut in vivo. Ectopic expression of human UAS-ALK in the Drosphila eye employing the pGMR-Gal4 driver line, which directs protein expression in the developing photoreceptors of the eye, does not result in any obvious phenotype in adult flies (Fig 3B,F) , and is similar to wild type controls (Fig 3A,E) . Expression of the various human ALK proteins confirmed by immunohistochemical analysis of developing eye discs (Fig 3I, J and K). Thus, the wild type ligand dependant human ALK RTK does not appear to be activated by endogenous Drosophila ligands, providing a clean background in which to analyse the activating potential of putative activating mutants of the human ALK as idenitifed in neuroblastoma patients.
Given the clean phenotypic background observed with overexpression of the wild type human ALK, we proceeded to investigate the in vivo signaling potential of the putative activated ALK F1174S mutant in the Drosophila system. In contrast to the results obtained with overexpression of wild type human ALK, we observed a robust ligand independent signaling upon ectopic expression of human ALK F1174S leading to the destruction of normal tissue morphology in the developing fly eye (Fig 3C, G) . (Fig.4B) . Importantly, expression of ALK in the absence of activating antibodies mediates only a minor fraction of neurite outgrowth (Fig.4B) .
However, upon stimulation of wild type ALK with mAb31 a similar level of neurite outgrowth to that of the F1174S and F1174L mutants is observed (Fig. 4B) . 
